555P TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial
Year: 2022
Type: article
Source: Annals of Oncology
Institutions: Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Fudan University, Obstetrics and Gynecology Hospital of Fudan University, Yuhuangding Hospital, Tianjin Medical University Cancer Institute and Hospital, Chongqing University, Chongqing Cancer Hospital, Liaoning Cancer Hospital & Institute, First Affiliated Hospital of Xi'an Jiaotong University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Tianjin Central Hospital of Gynecology Obstetrics, Capital Medical University, Beijing Obstetrics and Gynecology Hospital, Weifang People's Hospital, Hunan Cancer Hospital, Beijing Chao-Yang Hospital, Capital Medical University, University of Science and Technology of China, Anhui Provincial Hospital, Zhejiang Cancer Hospital, University of Chinese Academy of Sciences
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4296007387